Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany

Pediatric Pulmonology

Volumn 50, Issue 7, 2015, Pages 655-664

  Sommerburg, Olaf ^a,b   Hammermann, Jutta ^c   Lindner, Martin ^d   Stahl, Mirjam ^a,b   Muckenthaler, Martina ^a,b   Kohlmueller, Dirk ^e   Happich, Margit ^a   Kulozik, Andreas E ^a   Stopsack, Marina ^c   Gahr, Manfred ^c   Hoffmann, Georg F ^b,e   Mall, Marcus A ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b German Center for Lung Research (DZL)   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

biochemical screening; Cystic fibrosis; immunoreactive trypsinogen; newborn screening; pancreatitis associated protein

Indexed keywords

CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IMMUNOREACTIVE TRYPSINOGEN; PANCREATITIS ASSOCIATED PROTEIN; TRYPSINOGEN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; LECTIN; PANCREATITIS-ASSOCIATED PROTEIN; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; CYSTIC FIBROSIS; DRIED BLOOD SPOT TESTING; FALSE NEGATIVE RESULT; GENETIC SCREENING; GERMANY; HUMAN; MUTATIONAL ANALYSIS; NEWBORN; NEWBORN SCREENING; PREDICTIVE VALUE; PRIORITY JOURNAL; SWEAT TEST; BLOOD; COHORT ANALYSIS; FEMALE; INFANT; MALE; PROCEDURES; SENSITIVITY AND SPECIFICITY;

ANTIGENS, NEOPLASM; BIOMARKERS; BIOMARKERS, TUMOR; COHORT STUDIES; CYSTIC FIBROSIS; FEMALE; GERMANY; HUMANS; INFANT; INFANT, NEWBORN; LECTINS, C-TYPE; MALE; NEONATAL SCREENING; SENSITIVITY AND SPECIFICITY; TRYPSINOGEN;

EID: 84947046615     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23190     Document Type: Article

References (31)

1. Comeau AM, Accurso FJ, White TB, Campbell III, Hoffman PW, Parad G, Wilfond RB, Rosenfeld BS, Sontag M, Massie MK, et al., Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics 2007; 119: e495-5e518.
2. Castellani C, Southern KW, Brownlee K, Dankert RJ, Duff A, Farrell M, Mehta A, Munck A, Pollitt R, Sermet-Gaudelus I, et al., European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 2009; 8: 153-173.
3. Farrell PM, Lai HJ, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Hoffman G, Laessig R, Rock MJ, et al., Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! J Pediatr 2005; 147: S30-S36.
4. Munck A, Dhondt JL, Sahler C, Roussey M,. Implementation of the French nationwide cystic fibrosis newborn screening program. J Pediatr 2008; 153: 228-233.
5. Ross LF,. Newborn screening for cystic fibrosis: a lesson in public health disparities. J Pediatr 2008; 153: 308-313.
6. Sarles J, Berthezene P, Le LC, Somma C, Perini JM, Catheline M, Mirallie S, Luzet K, Roussey M, Farriaux JP, et al., Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis. J Pediatr 2005; 147: 302-305.
7. Gesetzüber genetische Untersuchungen bei Menschen. Gendiagnostikgesetz-GenDG 2009. Bundesgesetzblatt [I] p 2529.
8. Sommerburg O, Lindner M, Muckenthaler M, Kohlmueller D, Leible S, Feneberg R, Kulozik AE, Mall MA, Hoffmann GF,. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population. J Inherit Metab Dis 2010; 33: S263-S271.
9. Sommerburg O, Krulisova V, Hammermann J, Lindner M, Stahl M, Muckenthaler M, Kohlmueller D, Happich M, Kulozik AE, Votava F, et al., Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations. J Cyst Fibros 2014; 13: 15-23.
10. Sarles J, Giorgi R, Berthézène P, Munck A, Cheillan D, Dagorn JC, Roussey M,. Neonatal screening for cystic fibrosis: Comparing the performances of IRT/DNA and IRT/PAP. J Cyst Fibros 2014; 13: 384-390.
11. Hammermann J, Mense L, Stopsack M,. Newborn screening for cystic fibrosis with an IRT-PAP protocol. J Cyst Fibrosis 2011; 11: S47.
12. Lindner M, Wolf A, Moh B, Steinbach P, Kleihauer E, Bartram CR, Kulozik AE,. The spectrum of CFTR mutations in south-west German cystic fibrosis patients. Hum Genet 1992; 90: 267-269.
13. Tummler B, Storrs T, Dziadek V, Dork T, Meitinger T, Golla A, Bertele-Harms RM, Harms HK, Schroder E, Claass A, et al., Geographic distribution and origin of CFTR mutations in Germany. Hum Genet 1996; 97: 727-731.
14. Bowling FG, Brown AR,. Newborn screening for cystic fibrosis using an enzyme linked immunoabsorbent assay (ELISA) technique. Clin Chim Acta 1988; 171: 257-261.
15. Sarles J, Barthellemy S, Ferec C, Iovanna J, Roussey M, Farriaux JP, Toutain A, Berthelot J, Maurin N, Codet JP, et al., Blood concentrations of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 1999; 80: F118-F122.
16. Gregg RG, Wilfond BS, Farrell PM, Laxova A, Hassemer D, Mischler EH,. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols. Am J Hum Genet 1993; 52: 616-626.
17. Spence WC, Paulus-Thomas J, Orenstein DM, Naylor EW,. Neonatal screening for cystic fibrosis: addition of molecular diagnostics to increase specificity. Biochem Med Metab Biol 1993; 49: 200-211.
18. Gibson LE, Cooke RE,. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959; 23: 545-549.
19. Green A, Kirk J,. Guidelines for the performance of the sweat test for the diagnosis of cystic fibrosis. Ann Clin Biochem 2007; 44: 25-34.
20. Hirtz S, Gonska T, Seydewitz HH, Thomas J, Greiner P, Kuehr J, Brandis M, Eichler I, Rocha H, Lopes AI, et al., CFTR Cl- channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 2004; 127: 1085-1095.
21. Mall M, Kreda SM, Mengos A, Jensen TJ, Hirtz S, Seydewitz HH, Yankaskas J, Kunzelmann K, Riordan JR, Boucher RC,. The DeltaF508 mutation results in loss of CFTR function and mature protein in native human colon. Gastroenterology 2004; 126: 32-41.
22. Stock C, Hielscher T,. DTComPair: comparison of binary diagnostic tests in a paired study design. R package version 1.00. 2013.
23. Mayell SJ, Munck A, Craig JV, Sermet I, Brownlee KG, Schwarz MJ, Castellani C, Southern KW,. A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. J Cyst Fibros 2009; 8: 71-78.
24. Massie RJ, Poplawski N, Wilcken B, Goldblatt J, Byrnes C, Robertson C,. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. Eur Respir J 2001; 17: 1195-1200.
25. th 2014.
26. Vernooij-van Langen AM, Loeber JG, Elvers B, Triepels RH, Gille JJ, Van der Ploeg CP, Reijntjens S, Dompeling E, Dankert-Roelse JE,. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study. Thorax 2012; 67: 289-295.
27. Krulisova V, Balascakova M, Skalicka V, Piskackova T, Holubova A, Paderova J, Krenkova P, Dvorakova L, Zemkova D, Kracmar P, et al., Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA. EurJ Pediatr 2012; 171: 1223-1229.
28. Calvin J, Hogg SL, McShane D, McAuley SA, Iles R, Ross-Russell R, MacLean FM, Heeley ME, Heeley AF, Norfolk S, Cambridgeshire Paediatric Cystic Fibrosis N. Thirty-years of screening for cystic fibrosis in East Anglia. Arch Dis Child 2012; 97: 1043-1047.
29. Massie RJ, Curnow L, Glazner J, Armstrong DS, Francis I,. Lessons learned from 20 years of newborn screening for cystic fibrosis. Med J Aust 2012; 196: 67-70.
30. Comeau AM, Parad RB, Dorkin HL, Dovey M, Gerstle R, Haver K, Lapey A, O'Sullivan BP, Waltz DA, Zwerdling RG, et al., Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics 2004; 113: 1573-1581.
31. Baker MW, Groose M, Hoffman G, Rock M, Levy H, Farrel PM,. Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening. J Cyst Fibros 2011; 10: 278-281.